Sanofi and Regeneron’s Dupixent has received a positive CHMP opinion for treating chronic spontaneous urticaria in adults and adolescents. Phase 3 studies showed Dupixent significantly reduced itch and hives compared to a placebo after 24 weeks. If approved, Dupixent would be the first targeted medicine for CSU in the EU in over a decade. The safety profile of Dupixent was consistent with known data, with common adverse events including injection site reactions and hypertension. Dupixent is already approved for CSU in certain countries and has shown efficacy in treating various conditions.

Read more at GlobeNewswire: Sanofi and Regeneron’s Dupixent to treat